Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 15/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038015 | 1.00 | ABL1 (1.00) | ABL1LRRK2 | |
| SCHEMBL22362763 | 1.00 | ABL1 (1.00) | ABL1LRRK2 | |
| SCHEMBL29720216 | 1.00 | ABL1 (1.00) | ABL1LRRK2 | |
| SCHEMBL31037962 | 0.90 | LRRK2 (1.00) | ABL1LRRK2 | |
| SCHEMBL22362814 | 0.90 | LRRK2 (1.00) | ABL1LRRK2 | |
| SCHEMBL22363109 | 0.90 | LRRK2 (1.00) | ABL1LRRK2 | |
| SCHEMBL22362750 | 0.90 | LRRK2 (1.00) | ABL1LRRK2 | |
| SCHEMBL31037994 | 0.90 | LRRK2 (1.00) | ABL1LRRK2 | |
| SCHEMBL22362881 | 0.90 | LRRK2 (1.00) | ABL1LRRK2 | |
| SCHEMBL29720165 | 0.90 | LRRK2 (1.00) | ABL1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534461-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2026-01-27 | — | — | US | claimed |
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2023-11-16 | — | — | US | claimed |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2023-10-31 | — | — | US | claimed |
| US-20220242861-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2022-08-04 | — | — | US | claimed |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2021-11-11 | — | — | US | claimed |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | claimed |
| US-12534461-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2023-10-31 | — | — | US | disclosed |
| US-20220242861-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2022-08-04 | — | — | US | disclosed |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2021-11-11 | — | — | US | disclosed |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534461-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | SNCA, HCRTR2, HTT | ABL1 2917/4885LRRK2 452/4885 |
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | ABL1 531/4885LRRK2 82/4885 |
| US-20220242861-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS | VHL, PKD1, TP53 | ABL1 13/4885LRRK2 2365/4885 |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | SMN1; SMN2, SNCA, HTT | ABL1 531/4885LRRK2 82/4885 |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | ABL1 531/4885LRRK2 82/4885 |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | ABL1 531/4885LRRK2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.